Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 40 | 2024 | 22023 | 1.870 |
Why?
|
Immunotherapy | 25 | 2024 | 4626 | 1.650 |
Why?
|
Medical Oncology | 10 | 2024 | 2309 | 1.080 |
Why?
|
Melanoma | 14 | 2024 | 5690 | 0.910 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 29 | 2024 | 11656 | 0.890 |
Why?
|
Clinical Trials as Topic | 13 | 2024 | 8050 | 0.850 |
Why?
|
Mesothelioma | 6 | 2024 | 806 | 0.720 |
Why?
|
Biliary Tract Neoplasms | 3 | 2022 | 185 | 0.700 |
Why?
|
GPI-Linked Proteins | 6 | 2024 | 468 | 0.640 |
Why?
|
Drug Discovery | 3 | 2017 | 1053 | 0.610 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 8 | 2024 | 5247 | 0.600 |
Why?
|
Antibodies, Monoclonal | 12 | 2024 | 9131 | 0.550 |
Why?
|
Antibodies, Bispecific | 4 | 2024 | 191 | 0.550 |
Why?
|
Biological Therapy | 1 | 2018 | 138 | 0.550 |
Why?
|
National Cancer Institute (U.S.) | 4 | 2023 | 295 | 0.540 |
Why?
|
Interleukin-18 | 1 | 2018 | 251 | 0.530 |
Why?
|
Eye Diseases | 1 | 2021 | 652 | 0.510 |
Why?
|
Hepatitis, Autoimmune | 1 | 2018 | 173 | 0.510 |
Why?
|
Skin Neoplasms | 8 | 2024 | 5801 | 0.500 |
Why?
|
Drugs, Investigational | 1 | 2017 | 214 | 0.490 |
Why?
|
Myocarditis | 1 | 2022 | 766 | 0.480 |
Why?
|
Carcinoma, Merkel Cell | 4 | 2021 | 321 | 0.480 |
Why?
|
Lung Neoplasms | 11 | 2024 | 13243 | 0.470 |
Why?
|
Autoimmunity | 2 | 2019 | 1358 | 0.460 |
Why?
|
Pleural Neoplasms | 3 | 2024 | 609 | 0.420 |
Why?
|
Petunia | 2 | 2023 | 3 | 0.420 |
Why?
|
Carcinoma, Hepatocellular | 3 | 2023 | 2295 | 0.420 |
Why?
|
Rare Diseases | 3 | 2024 | 619 | 0.400 |
Why?
|
Research Design | 3 | 2023 | 6165 | 0.400 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1787 | 0.390 |
Why?
|
Antineoplastic Agents | 9 | 2024 | 13625 | 0.380 |
Why?
|
Humans | 110 | 2024 | 759098 | 0.380 |
Why?
|
Developing Countries | 1 | 2024 | 2862 | 0.380 |
Why?
|
Asbestos | 1 | 2013 | 251 | 0.370 |
Why?
|
Iodine Radioisotopes | 1 | 2014 | 1030 | 0.370 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 380 | 0.360 |
Why?
|
Adenoma, Pleomorphic | 1 | 2010 | 75 | 0.340 |
Why?
|
Liver Neoplasms | 3 | 2023 | 4313 | 0.330 |
Why?
|
Carcinoma, Papillary | 1 | 2014 | 785 | 0.330 |
Why?
|
Thyroidectomy | 1 | 2014 | 901 | 0.320 |
Why?
|
Hodgkin Disease | 3 | 2023 | 1381 | 0.320 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 1525 | 0.320 |
Why?
|
Extracellular Matrix Proteins | 1 | 2013 | 829 | 0.310 |
Why?
|
Patient Selection | 1 | 2020 | 4268 | 0.310 |
Why?
|
Adverse Drug Reaction Reporting Systems | 3 | 2024 | 488 | 0.300 |
Why?
|
Molecular Targeted Therapy | 4 | 2021 | 2801 | 0.290 |
Why?
|
Combined Modality Therapy | 8 | 2022 | 8548 | 0.270 |
Why?
|
Anilides | 3 | 2024 | 409 | 0.270 |
Why?
|
Salivary Gland Neoplasms | 1 | 2010 | 302 | 0.270 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2018 | 2161 | 0.260 |
Why?
|
Neoplasm Staging | 10 | 2024 | 11125 | 0.260 |
Why?
|
Tuberculosis | 1 | 2019 | 2002 | 0.260 |
Why?
|
Pandemics | 3 | 2024 | 8604 | 0.250 |
Why?
|
Flowers | 2 | 2023 | 30 | 0.250 |
Why?
|
HIV Infections | 5 | 2023 | 17126 | 0.250 |
Why?
|
Trinidad and Tobago | 1 | 2024 | 12 | 0.240 |
Why?
|
Neuroendocrine Tumors | 2 | 2021 | 649 | 0.230 |
Why?
|
Adrenocortical Carcinoma | 1 | 2024 | 86 | 0.220 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2023 | 43 | 0.220 |
Why?
|
Aged | 38 | 2024 | 168615 | 0.220 |
Why?
|
Fibromatosis, Aggressive | 1 | 2024 | 125 | 0.220 |
Why?
|
Middle Aged | 42 | 2024 | 219628 | 0.220 |
Why?
|
Th1 Cells | 2 | 2019 | 1004 | 0.220 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2024 | 666 | 0.220 |
Why?
|
Genomics | 4 | 2024 | 5778 | 0.220 |
Why?
|
Urogenital Neoplasms | 1 | 2024 | 135 | 0.210 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 224 | 0.210 |
Why?
|
Antibodies, Blocking | 1 | 2023 | 229 | 0.210 |
Why?
|
Paraneoplastic Syndromes | 1 | 2024 | 155 | 0.210 |
Why?
|
Plant Proteins | 2 | 2023 | 370 | 0.210 |
Why?
|
Occupational Exposure | 1 | 2013 | 1806 | 0.200 |
Why?
|
Gallbladder Neoplasms | 1 | 2024 | 191 | 0.200 |
Why?
|
Radiation Dosage | 2 | 2020 | 1955 | 0.200 |
Why?
|
Kidney Neoplasms | 3 | 2024 | 4312 | 0.200 |
Why?
|
Aged, 80 and over | 22 | 2024 | 58864 | 0.190 |
Why?
|
Bees | 1 | 2021 | 45 | 0.190 |
Why?
|
Thyroid Neoplasms | 1 | 2014 | 2329 | 0.190 |
Why?
|
SEER Program | 2 | 2024 | 1531 | 0.190 |
Why?
|
Carcinoma, Renal Cell | 3 | 2023 | 3216 | 0.180 |
Why?
|
Leukemia, B-Cell | 1 | 2021 | 84 | 0.180 |
Why?
|
Monitoring, Immunologic | 1 | 2021 | 96 | 0.180 |
Why?
|
Female | 48 | 2024 | 390174 | 0.180 |
Why?
|
Male | 44 | 2024 | 358602 | 0.180 |
Why?
|
Consensus | 4 | 2023 | 3091 | 0.180 |
Why?
|
Truth Disclosure | 1 | 2024 | 432 | 0.170 |
Why?
|
Arabidopsis | 1 | 2023 | 464 | 0.170 |
Why?
|
Adult | 32 | 2024 | 219353 | 0.170 |
Why?
|
Cancer Vaccines | 2 | 2020 | 1048 | 0.170 |
Why?
|
Neoplasm, Residual | 1 | 2024 | 1007 | 0.160 |
Why?
|
Recombinant Fusion Proteins | 3 | 2024 | 3729 | 0.160 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 12270 | 0.160 |
Why?
|
Hemangiosarcoma | 1 | 2021 | 218 | 0.160 |
Why?
|
Sezary Syndrome | 1 | 2019 | 77 | 0.160 |
Why?
|
Maryland | 1 | 2019 | 274 | 0.160 |
Why?
|
Pyrimidinones | 1 | 2021 | 383 | 0.160 |
Why?
|
Receptor, erbB-2 | 2 | 2024 | 2524 | 0.150 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2023 | 685 | 0.150 |
Why?
|
Retrospective Studies | 12 | 2024 | 80125 | 0.150 |
Why?
|
Protein Kinase Inhibitors | 2 | 2021 | 5637 | 0.150 |
Why?
|
Joints | 1 | 2020 | 322 | 0.150 |
Why?
|
Multiple Organ Failure | 1 | 2020 | 387 | 0.150 |
Why?
|
Mycosis Fungoides | 1 | 2019 | 168 | 0.150 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2018 | 79 | 0.150 |
Why?
|
Kupffer Cells | 1 | 2018 | 143 | 0.150 |
Why?
|
Antibodies, Neutralizing | 3 | 2024 | 1930 | 0.150 |
Why?
|
Pyridines | 3 | 2024 | 2876 | 0.140 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 243 | 0.140 |
Why?
|
United States | 11 | 2024 | 72238 | 0.140 |
Why?
|
Bile Duct Neoplasms | 1 | 2022 | 601 | 0.140 |
Why?
|
Virus Internalization | 1 | 2020 | 495 | 0.140 |
Why?
|
Granuloma | 1 | 2019 | 327 | 0.140 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2018 | 214 | 0.140 |
Why?
|
Immunity | 2 | 2020 | 997 | 0.130 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2019 | 288 | 0.130 |
Why?
|
Neoplasms, Experimental | 1 | 2021 | 1230 | 0.130 |
Why?
|
Guanine | 2 | 2014 | 278 | 0.130 |
Why?
|
Glutamates | 2 | 2014 | 391 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2024 | 3476 | 0.130 |
Why?
|
Oximes | 1 | 2017 | 306 | 0.130 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2020 | 421 | 0.130 |
Why?
|
Natural Language Processing | 1 | 2024 | 1128 | 0.120 |
Why?
|
Matrix Metalloproteinases | 1 | 2018 | 392 | 0.120 |
Why?
|
Lymphoma, B-Cell | 1 | 2022 | 935 | 0.120 |
Why?
|
Immunoconjugates | 2 | 2024 | 881 | 0.120 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2022 | 800 | 0.120 |
Why?
|
Diarrhea | 1 | 2021 | 1340 | 0.120 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2024 | 5628 | 0.120 |
Why?
|
Recurrence | 6 | 2024 | 8465 | 0.120 |
Why?
|
Salvage Therapy | 1 | 2021 | 1265 | 0.120 |
Why?
|
Pancreatic Neoplasms | 1 | 2012 | 5312 | 0.120 |
Why?
|
Disease-Free Survival | 5 | 2024 | 6814 | 0.120 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2017 | 1343 | 0.110 |
Why?
|
Congresses as Topic | 1 | 2019 | 802 | 0.110 |
Why?
|
Fatal Outcome | 1 | 2019 | 1833 | 0.110 |
Why?
|
Myelodysplastic Syndromes | 1 | 2023 | 1396 | 0.110 |
Why?
|
Animals | 12 | 2024 | 167531 | 0.110 |
Why?
|
Immunomodulation | 1 | 2017 | 548 | 0.110 |
Why?
|
Antibodies, Viral | 1 | 2024 | 3143 | 0.110 |
Why?
|
Medical Records | 1 | 2018 | 1405 | 0.110 |
Why?
|
Colitis | 1 | 2021 | 1230 | 0.110 |
Why?
|
Herpesvirus 4, Human | 1 | 2018 | 1074 | 0.110 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2014 | 327 | 0.100 |
Why?
|
Virus Replication | 1 | 2020 | 2431 | 0.100 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2018 | 973 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1093 | 0.100 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2018 | 607 | 0.100 |
Why?
|
Oncolytic Virotherapy | 1 | 2018 | 515 | 0.100 |
Why?
|
Program Evaluation | 1 | 2020 | 2487 | 0.100 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 1627 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2416 | 0.100 |
Why?
|
Pentostatin | 1 | 2011 | 26 | 0.100 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 2810 | 0.100 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2013 | 268 | 0.100 |
Why?
|
Prospective Studies | 10 | 2024 | 54190 | 0.100 |
Why?
|
Immunotoxins | 1 | 2012 | 175 | 0.100 |
Why?
|
Leukocytes, Mononuclear | 3 | 2024 | 1825 | 0.090 |
Why?
|
Treatment Outcome | 12 | 2024 | 64867 | 0.090 |
Why?
|
Imidazoles | 1 | 2017 | 1175 | 0.090 |
Why?
|
Societies, Medical | 1 | 2023 | 3890 | 0.090 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2901 | 0.090 |
Why?
|
Pyrazoles | 1 | 2021 | 1989 | 0.090 |
Why?
|
Phylogeny | 3 | 2024 | 2765 | 0.090 |
Why?
|
Perception | 1 | 2017 | 1189 | 0.090 |
Why?
|
Colorectal Neoplasms | 2 | 2021 | 6853 | 0.090 |
Why?
|
Dendritic Cells | 2 | 2020 | 2720 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1786 | 0.090 |
Why?
|
Enzyme Inhibitors | 1 | 2021 | 3722 | 0.090 |
Why?
|
Neoplasm Metastasis | 4 | 2022 | 4883 | 0.090 |
Why?
|
Radiotherapy Dosage | 3 | 2022 | 2895 | 0.090 |
Why?
|
T-Lymphocyte Subsets | 1 | 2018 | 1789 | 0.080 |
Why?
|
Remission Induction | 3 | 2024 | 2388 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2530 | 0.080 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3694 | 0.080 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 3449 | 0.080 |
Why?
|
Signal Transduction | 3 | 2018 | 23328 | 0.080 |
Why?
|
Deoxycytidine | 2 | 2011 | 860 | 0.080 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2022 | 2277 | 0.080 |
Why?
|
Electronic Health Records | 2 | 2024 | 4737 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 4 | 2024 | 6530 | 0.080 |
Why?
|
Communication | 1 | 2023 | 3846 | 0.080 |
Why?
|
Immune Tolerance | 1 | 2018 | 2238 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2023 | 2891 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2024 | 4163 | 0.080 |
Why?
|
Prednisone | 2 | 2024 | 1563 | 0.080 |
Why?
|
Indoles | 1 | 2017 | 1828 | 0.080 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2192 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2020 | 2016 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3606 | 0.070 |
Why?
|
Mycobacterium tuberculosis | 1 | 2019 | 1905 | 0.070 |
Why?
|
Liver | 1 | 2023 | 7514 | 0.070 |
Why?
|
Drug Combinations | 1 | 2013 | 2021 | 0.070 |
Why?
|
Sulfonamides | 1 | 2017 | 1972 | 0.070 |
Why?
|
Peritoneal Neoplasms | 1 | 2013 | 706 | 0.070 |
Why?
|
Adjuvants, Immunologic | 2 | 2023 | 1031 | 0.070 |
Why?
|
Autoimmune Diseases | 1 | 2019 | 2236 | 0.070 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4893 | 0.070 |
Why?
|
B-Lymphocytes | 2 | 2018 | 4721 | 0.070 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5366 | 0.070 |
Why?
|
Young Adult | 6 | 2024 | 58477 | 0.070 |
Why?
|
Software | 1 | 2020 | 4421 | 0.070 |
Why?
|
Breast Neoplasms | 2 | 2024 | 21019 | 0.060 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2013 | 1919 | 0.060 |
Why?
|
Fluorouracil | 1 | 2010 | 1621 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2011 | 2218 | 0.060 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2019 | 2420 | 0.060 |
Why?
|
1-Acylglycerophosphocholine O-Acyltransferase | 1 | 2024 | 9 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 1 | 2020 | 3772 | 0.060 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 3052 | 0.060 |
Why?
|
Maytansine | 1 | 2024 | 86 | 0.060 |
Why?
|
Disease Progression | 4 | 2023 | 13470 | 0.060 |
Why?
|
Phytochrome A | 1 | 2023 | 2 | 0.060 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2023 | 772 | 0.060 |
Why?
|
Prognosis | 4 | 2020 | 29559 | 0.060 |
Why?
|
Pregnancy | 2 | 2024 | 29650 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.050 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2024 | 159 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3208 | 0.050 |
Why?
|
Chemokine CCL5 | 1 | 2022 | 214 | 0.050 |
Why?
|
Interleukin-5 | 1 | 2022 | 269 | 0.050 |
Why?
|
Philadelphia Chromosome | 1 | 2022 | 117 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2022 | 256 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 13285 | 0.050 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 71 | 0.050 |
Why?
|
Vaccination | 2 | 2024 | 3354 | 0.050 |
Why?
|
Azetidines | 1 | 2021 | 137 | 0.050 |
Why?
|
Survival Rate | 3 | 2020 | 12793 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39213 | 0.050 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 11903 | 0.040 |
Why?
|
Tacrolimus | 1 | 2024 | 726 | 0.040 |
Why?
|
Volatile Organic Compounds | 1 | 2021 | 83 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2014 | 876 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 642 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2010 | 3684 | 0.040 |
Why?
|
Drug Repositioning | 1 | 2021 | 231 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6490 | 0.040 |
Why?
|
Organ Culture Techniques | 1 | 2021 | 796 | 0.040 |
Why?
|
Survival Analysis | 2 | 2024 | 10181 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2020 | 878 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2019 | 8950 | 0.040 |
Why?
|
Tumor Burden | 1 | 2024 | 1886 | 0.040 |
Why?
|
Creatinine | 1 | 2024 | 1904 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2020 | 736 | 0.040 |
Why?
|
Adolescent | 5 | 2024 | 87551 | 0.040 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2020 | 496 | 0.040 |
Why?
|
Mammals | 1 | 2022 | 1130 | 0.030 |
Why?
|
Cytokines | 2 | 2022 | 7290 | 0.030 |
Why?
|
Cisplatin | 2 | 2014 | 1643 | 0.030 |
Why?
|
Doxorubicin | 1 | 2023 | 2202 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2022 | 2569 | 0.030 |
Why?
|
Dogs | 1 | 2021 | 3839 | 0.030 |
Why?
|
Drug Interactions | 1 | 2020 | 1422 | 0.030 |
Why?
|
Methotrexate | 1 | 2022 | 1715 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1180 | 0.030 |
Why?
|
Data Collection | 1 | 2024 | 3317 | 0.030 |
Why?
|
Databases, Factual | 2 | 2021 | 8001 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2024 | 1439 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2234 | 0.030 |
Why?
|
Lymphocytes | 1 | 2022 | 2601 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2023 | 3518 | 0.030 |
Why?
|
ADP Ribose Transferases | 1 | 2014 | 90 | 0.030 |
Why?
|
Exotoxins | 1 | 2014 | 121 | 0.030 |
Why?
|
Risk Factors | 3 | 2017 | 74167 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2012 | 21992 | 0.030 |
Why?
|
Hypothyroidism | 1 | 2019 | 666 | 0.030 |
Why?
|
Mice | 4 | 2024 | 80993 | 0.030 |
Why?
|
Piperidines | 1 | 2021 | 1648 | 0.030 |
Why?
|
Evolution, Molecular | 1 | 2021 | 1883 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9271 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2022 | 1583 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2013 | 398 | 0.030 |
Why?
|
Body Weight | 1 | 2023 | 4606 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 308 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2024 | 4526 | 0.030 |
Why?
|
DNA Repair | 1 | 2021 | 2039 | 0.030 |
Why?
|
Genome | 1 | 2020 | 1739 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2020 | 1448 | 0.020 |
Why?
|
CA-125 Antigen | 1 | 2014 | 280 | 0.020 |
Why?
|
Sex Distribution | 1 | 2017 | 2294 | 0.020 |
Why?
|
Folic Acid Antagonists | 1 | 2011 | 75 | 0.020 |
Why?
|
Hypersensitivity | 1 | 2020 | 1158 | 0.020 |
Why?
|
Age Distribution | 1 | 2017 | 2891 | 0.020 |
Why?
|
Virulence Factors | 1 | 2014 | 508 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2021 | 4715 | 0.020 |
Why?
|
Child | 3 | 2023 | 79604 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2017 | 2434 | 0.020 |
Why?
|
Infant | 2 | 2023 | 35940 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2022 | 4299 | 0.020 |
Why?
|
Vinblastine | 1 | 2011 | 487 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3062 | 0.020 |
Why?
|
Child, Preschool | 2 | 2023 | 41932 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2011 | 776 | 0.020 |
Why?
|
Bacterial Toxins | 1 | 2014 | 931 | 0.020 |
Why?
|
Risk | 1 | 2020 | 9622 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2011 | 482 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41266 | 0.020 |
Why?
|
Drug Therapy | 1 | 2011 | 504 | 0.020 |
Why?
|
Pneumonia | 1 | 2019 | 2139 | 0.020 |
Why?
|
Registries | 1 | 2023 | 8435 | 0.020 |
Why?
|
Cause of Death | 1 | 2017 | 3719 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2011 | 818 | 0.020 |
Why?
|
Medicare | 1 | 2024 | 6763 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2023 | 8936 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16524 | 0.020 |
Why?
|
Proteins | 1 | 2020 | 6024 | 0.020 |
Why?
|
Pain | 1 | 2020 | 5059 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9372 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5214 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3793 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2020 | 7838 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 7790 | 0.010 |
Why?
|
Smoking | 1 | 2020 | 9066 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 26099 | 0.010 |
Why?
|
Comorbidity | 1 | 2017 | 10550 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6964 | 0.010 |
Why?
|
Aging | 1 | 2021 | 8633 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2011 | 6143 | 0.010 |
Why?
|
Risk Assessment | 1 | 2022 | 24049 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15639 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 40083 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 10825 | 0.010 |
Why?
|
Bacterial Proteins | 1 | 2011 | 3824 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2011 | 10069 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36164 | 0.010 |
Why?
|